SurgePays - SURG Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SurgePays in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SURG shares.
View SURG analyst ratings or view top-rated stocks.

2 analysts have issued 1 year price objectives for SurgePays' stock. Their SURG share price forecasts range from $7.00 to $8.00. On average, they anticipate the company's share price to reach $7.50 in the next year. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for SURG or view top-rated stocks among Wall Street analysts.

SurgePays' stock was trading at $2.02 on January 1st, 2022. Since then, SURG shares have increased by 215.3% and is now trading at $6.37.
View the best growth stocks for 2022 here.

SurgePays saw a increase in short interest in July. As of July 31st, there was short interest totaling 946,100 shares, an increase of 48.0% from the July 15th total of 639,100 shares. Based on an average daily volume of 153,900 shares, the days-to-cover ratio is currently 6.1 days. Approximately 8.4% of the shares of the stock are sold short.
View SurgePays' Short Interest.

SurgePays, Inc. (NASDAQ:SURG) issued its quarterly earnings results on Monday, May, 16th. The medical equipment provider reported ($0.10) earnings per share for the quarter. The medical equipment provider earned $21.14 million during the quarter.

SurgePays issued an update on its FY 2022 earnings guidance on Friday, August, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $130.00M-, compared to the consensus revenue estimate of $126.97 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other SurgePays investors own include Agilent Technologies (A), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Celldex Therapeutics (CLDX), Genocea Biosciences (GNCA), GTX (GTXI), Idera Pharmaceuticals (IDRA), Microbot Medical (MBOT), Progenics Pharmaceuticals (PGNX) and Rigel Pharmaceuticals (RIGL).

SurgePays trades on the NASDAQ under the ticker symbol "SURG."

Shares of SURG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SURG stock can currently be purchased for approximately $6.37.

SurgePays (NASDAQ:SURG) has a market capitalization of $78.01 million and generates $51.06 million in revenue each year. The medical equipment provider earns $-13,530,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis.

SurgePays' mailing address is 3845 Corporate Centre Dr, O'FALLON, MO 63368-8678, United States. The official website for the company is www.surgeholdings.com. The medical equipment provider can be reached via phone at (901) 302-9587 or via email at invest@surgepays.com.